Treatment of spondyloarthropathy: The potential for agents other than TNF inhibitors

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 455-459

  Her, Minyoung ^a   Kavanaugh, Arthur ^b  

^a Inje University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anklyosing spondylitis; biologic agents; psoriatic arthritis; spondyloarthropathy; treatment

Indexed keywords

ABATACEPT; APREMILAST; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 17; METHOTREXATE; PHOSPHODIESTERASE IV; RITUXIMAB; SARILUMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

B LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKINS; MOLECULAR TARGETED THERAPY; PHOSPHODIESTERASE 4 INHIBITORS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879890395     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283620177     Document Type: Review

References (43)

1. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591. (Pubitemid 40216323)
2. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005; 53:856-863. (Pubitemid 41811126)
3. Baeten D, Sieper J, Emery P, et al. The anti IL-17 A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2011; 70 (Suppl 3):127.
4. Ritchlin CT, Gottlieb AB, McInnes IB, et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64 (Suppl):S1080.
5. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59:135-140. (Pubitemid 30305612)
6. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845-2851. (Pubitemid 44497763)
7. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twentyfour- week clinical trial. Arthritis Rheum 2010; 62:1290-1297.
8. Song IH, Heldmann F, Rudwaleit M, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013; 72:305-306.
9. Wendling D, Dougados M, Berenbaum F, et al. A nationwide series: data from the AIR Registry of the French Society of Rheumatology. J Rheumatol 2012; 39:2327-2331.
10. Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012; 71:1868-1871.
11. Mease P, Kavanaugh A, Genovese M, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. Arthritis Rheum 2010; 62 (Suppl):S818.
12. Iannone F, Lapadula G. The inhibitor of costimulation of T cells: abatacept. J Rheumatol 2012; 89 (Suppl):100-102.
13. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70:1108-1110.
14. Lekpa FK, Farrenq V, Canoui-Poitrine F, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012; 79:47-50.
15. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63:939-948.
16. Atzeni F, Ventura D, Batticciotto A, et al. Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol 2012; 89 (Suppl):97-99.
17. Elkayam O, Yaron I, Shirazi I, et al. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000; 19:101-105. (Pubitemid 30189841)
18. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551-1557. (Pubitemid 44799664)
19. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26:211-215. (Pubitemid 46020247)
20. François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006; 65:713-720. (Pubitemid 43799168)
21. Hayer S, Niederreiter B, Nagelreiter I, et al. Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Ann Rheum Dis 2010; 69:1403-1406.
22. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010; 77:625-626.
23. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011; 38:1527.
24. Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthropathies: about 18 cases. Ann Rheum Dis 2011; 70 (Suppl 3):128.
25. Sieper J, Porter-Brown B, Thompson L, et al. Tocilizumab is not effective for the treatment of ankylosing spondylitis: results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2012; 71 (Suppl 3):110.
26. Sieper J, Inman RD, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. double-blind, placebo-controlled, international study. Ann Rheum Dis 2012; 71 (Suppl 3): 111.
27. Lekpa FK, Poulain C, Wendling D, et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Res Ther 2012; 14:R53.
28. Miossec P, Kolls JK. Targeting IL-17 and TH 17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11:763-776.
29. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58:2307-2317.
30. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-1656.
31. Appel H, Maier R, Wu P, et al. Analysis of IL-17(p) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13:R95.
32. McInnes I, Sieper J, Braun J, et al. Antiinterleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63 (Suppl):S306.
33. Cauli A, Mathieu A. Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis. J Rheumatol 2012; 89 (Suppl):15-18.
34. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009; 1182:97-110.
35. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329-1337. (Pubitemid 350041542)
36. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gtp CD3pCD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069-1076.
37. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007; 46:417-425. (Pubitemid 46344652)
38. Goldminz AM, Gottlieb AB. Ustekinumab for psoriasis and psoriatic arthritis. J Rheumatol 2012; 89 (Suppl):86-89.
39. Kavanaugh A, McInnes IB, Gottlieb AB, et al. Ustekinumab in patient with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, PSUMMIT I study. Arthritis Rheum 2012; 64 (Suppl):S1083.
40. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83:1583-1590.
41. Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2012. [Epub ahead of print].
42. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64:3156-3167.
43. Kavanaugh A, Mease P, Gomez-Reino J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, I patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial. Arthritis Rheum 2012; 64:4172-4173.